Lumida
/CELC
⌘K
Celcuity Inc

Celcuity Inc

CELC
$88.38USD+0.10%+0.09 today

MARKET CAP

4.3B

P/E (TTM)

FWD P/E

DAY RANGE

$86 – $91

52W RANGE

$13
$151

AI Summary

Stalk
TrimMedium

CELC remains in a Stage 4 decline with a clear sequence of lower highs and lower lows reinforced by a bearish primary pattern. Medium-term bias is bearish, but near-term price is extended below declining EMAs and oversold, offering no optimal Sell Now setup. Execution is deferred: plan to Trim into any relief bounce into the 9/20 EMA and 50 DMA confluence for higher-probability entries.

  • Phase III Victoria I trial reported 9.3-month median PFS for gadotelicib.
  • FDA PDUFA date set for July 17, 2026; management sees no delay risk.
  • Q1 2026 net loss rose to $52.8M vs $37M last year.
Full analysis →
Insider Trades9 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jun 2, 2026BuyCELCLance G. LaingChief Science Officer1,000$9.89$4.3B-41.48%+556.12%$9.9K+0.08%Trim
Sep 2, 2025BuyCELCBrian F. SullivanChief Executive Officer104,340$8.05$4.3B-41.48%+556.12%$839.9K+8.24%Trim
Apr 14, 2025SellCELCBrian F. SullivanChief Executive Officer16,310$9.75$4.3B-41.48%+556.12%$159.0K+0.00%Trim
Mar 3, 2025SellCELCBrian F. SullivanChief Executive Officer243,030$8.90$4.3B-41.48%+556.12%$2.2M+0.00%Trim
Aug 20, 2024SellCELCBrian F. SullivanChief Executive Officer378,206$17.04$4.3B-41.48%+556.12%$6.4M+0.00%Trim
Apr 26, 2024SellCELCBrian F. SullivanChief Executive Officer90,050$15.92$4.3B-41.48%+556.12%$1.4M+0.00%Trim
Mar 18, 2024SellCELCBrian F. SullivanChief Executive Officer1,531,794$17.83$4.3B-41.48%+556.12%$27.3M+0.00%Trim
Jan 30, 2024SellCELCBrian F. SullivanChief Executive Officer170,000$15.21$4.3B-41.48%+556.12%$2.6M+0.00%Trim
Dec 27, 2023SellCELCBrian F. SullivanChief Executive Officer3,466,694$14.90$4.3B-41.48%+556.12%$51.7M+0.00%Trim